Top

Published in:

01-12-2011 | Urinary Tract Infections (Jack D. Sobel, Section Editor)

Recurrent Urinary Tract Infections in Kidney Transplant Recipients

Authors: Subhashis Mitra, George John Alangaden

Published in: Current Infectious Disease Reports | Issue 6/2011

Abstract

Urinary tract infections (UTIs) are the most common infectious complication after kidney transplantation (KT). Recurrent UTIs after KT can contribute to increased morbidity and may also be associated with graft loss and mortality. Though several risk factors like female gender, diabetes mellitus, presence of ureteric stents, native kidney disease with urological malformations and re-transplantation have been associated with recurrent UTIs after KT, vesicoureteric reflux appears to be a unique risk factor in this patient population. The emergence of drug-resistant pathogens as causative agents for post-transplant recurrent UTIs poses a significant therapeutic challenge. The use of pathogen-specific antibiotic therapy guided by culture and sensitivity data is warranted. The optimal duration of antimicrobial therapy for recurrent UTIs in renal transplant recipients remains uncertain.

2009 OPTN/SRTR annual report. Available at http://www.ustransplant.org/annual_reports/current/default.htm. Accessed March 15, 2011

Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20:401–9. doi:10.1111/j.1399-0012.2006.00519.x.PubMedCrossRef

Alangaden G. Urinary tract infections in renal transplant recipients. Curr Infect Dis Rep. 2007;9:475–9.PubMedCrossRef

Veroux M, Giuffrida G, Corona D, et al. Infective complications in renal allograft recipients: epidemiology and outcome. Transplant Proc. 2008;40:1873–6. doi:10.1016/j.transproceed.2008.05.065.PubMedCrossRef

Pelle G, Vimont S, Levy PP, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant. 2007;7:899–907. doi:10.1111/j.1600-6143.2006.01700.x.PubMedCrossRef

Abbott KC, Oliver 3rd JD, Hypolite I, et al. Hospitalizations for bacterial septicemia after renal transplantation in the united states. Am J Nephrol. 2001;21:120–7.PubMedCrossRef

Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis. 2004;44:353–62.PubMedCrossRef

Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant. 2005;19:230–5. doi:10.1111/j.1399-0012.2005.00327.x.PubMedCrossRef

• Song JC, Hwang HS, Yoon HE, et al. Endoscopic subureteral polydimethylsiloxane injection and prevention of recurrent acute graft pyelonephritis. Nephron Clin Pract. 2010;117:c385–c9. doi:10.1159/000321526. A recent study evaluating the effect of subureteral polydimethylsiloxane (PDS) Injection for the correction of VUR and recurrence of AGPN in KT recipients.PubMedCrossRef

10.

• Dupont PJ, Psimenou E, Lord R, et al. Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation. 2007;84:351–5. doi:10.1097/01.tp.0000275377.09660.fa. A retrospective study of late-onset recurrent UTIs that identified renal scarring in patients with late recurrent UTIs, though this was not associated with graft loss.PubMedCrossRef

11.

Raygada RL, Doshi M, Gruber SA, et al. Symptomatic urinary tract infections in renal transplant recipients: 6 year experience at a single transplant center. Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, October 25–28, 2008

12.

Albert X, Huertas I, Pereiro II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209. doi:10.1002/14651858.CD001209.pub2

13.

• Kamath NS, John GT, Neelakantan N, et al. Acute graft pyelonephritis following renal transplantation. Transpl Infect Dis. 2006;8(3):140–7. doi:10.1111/j.1399-3062.2006.00148.x. A retrospective study of 1022 KT recipients over a 10 year period. Authors observed that placement of ureteric stent, CMV disease and native kidney disease with urological malformations were associated with recurrent AGPN episodes.PubMedCrossRef

14.

Giral M, Pascuariello G, Karam G, et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int. 2002;61:1880–6. doi:10.1046/j.1523-1755.2002.00323.x.PubMedCrossRef

15.

Memikoglu KO, Keven K, Sengul S, et al. Urinary tract infections following renal transplantation: a single-center experience. Transplant Proc. 2007;39:3131–4. doi:10.1016/j.transproceed.2007.10.005.PubMedCrossRef

16.

Goya N, Tanabe K, Iguchi Y, et al. Prevalence of urinary tract infection during outpatient follow-up after renal transplantation. Infection. 1997;25:101–5.PubMedCrossRef

17.

Valera B, Gentil MA, Cabello V, et al. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc. 2006;38:2414–5. doi:10.1016/j.transproceed.2006.08.018.PubMedCrossRef

18.

Chan PC, Cheng IK, Wong KK, et al. Urinary tract infections in post-renal transplant patients. Int Urol Nephrol. 1990;22(4):389–96.PubMedCrossRef

19.

Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol. 2002;12:125–30.PubMedCrossRef

20.

Senger SS, Arslan H, Azap OK, et al. Urinary tract infections in renal transplant recipients. Transplant Proc. 2007;39:1016–7. doi:10.1016/j.transproceed.2007.02.060.PubMedCrossRef

21.

Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone Elsevier; 2010. p. 957–85.

22.

Buckley O, Geoghegan T, O'Brien J, Torreggiani WC. Vesicoureteric reflux in the adult. Br J Radiol. 2007;80(954):392–400. doi:10.1259/bjr/60682848.PubMedCrossRef

23.

Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev. 2005;(4):CD004925. doi:10.1002/14651858.CD004925.pub2

24.

Pinheiro HS, Mituiassu AM, Carminatti M, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients. Transplant Proc. 2010;42:486–7. doi:10.1016/j.transproceed.2010.02.002.PubMedCrossRef

25.

Maillard O, Corvec S, Dantal J, et al. Emergence of high ampicillin-resistant enterococcus faecium isolates in a kidney transplant ward: role of antibiotic pressure and cross transmission. Microb Drug Resist. 2010;16(2):123–8. doi:10.1089/mdr.2009.0095.PubMedCrossRef

26.

Rivera-Sanchez R, Delgado-Ochoa D, Flores-Paz RR, et al. Prospective study of urinary tract infection surveillance after kidney transplantation. BMC Infect Dis. 2010;10:245. doi:10.1186/1471-2334-10-245.PubMedCrossRef

27.

Nankivell BJ, Cohn DA, Spicer ST, et al. Diagnosis of kidney transplant obstruction using Mag3 diuretic renography. Clin Transplant. 2001;15(1):11–8.PubMedCrossRef

28.

Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20. doi:10.1093/cid/ciq257.PubMedCrossRef

29.

Saemann M, Horl WH. Urinary tract infection in renal transplant recipients. Eur J Clin Invest. 2008;38 Suppl 2:58–65. doi:10.1111/j.1365-2362.2008.02014.x.PubMedCrossRef

30.

Maraha B, Bonten H, van Hooff H, et al. Infectious complications and antibiotic use in renal transplant recipients during a 1-year follow-up. Clin Microbiol Infect. 2001;7(11):619–25.PubMedCrossRef

31.

Rabkin DG, Stifelman MD, Birkhoff J, et al. Early catheter removal decreases incidence of urinary tract infections in renal transplant recipients. Transplant Proc. 1998;30(8):4314–6.PubMedCrossRef

32.

Renoult E, Aouragh F, Mayeux D, et al. Factors influencing early urinary tract infections in kidney transplant recipients. Transplant Proc. 1994;26(4):2056–8.PubMed

33.

Munoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin Infect Dis. 2001;33 Suppl 1:S53–7. doi:10.1086/320905.PubMedCrossRef

34.

Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89(3):255–74.PubMedCrossRef

35.

Maki DG, Fox BC, Kuntz J, et al. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med. 1992;119(1):11–24.PubMed

36.

Khosroshahi HT, Mogaddam AN, Shoja MM. Efficacy of high-dose trimethoprim-sulfamethoxazol prophylaxis on early urinary tract infection after renal transplantation. Transplant Proc. 2006;38(7):2062–4. doi:10.1016/j.transproceed.2006.06.111.PubMedCrossRef

37.

Reek C, Noster M, Burmeister D, et al. Urological complications of renal transplantation: a series of 900 cases. Transplant Proc. 2003;35(6):2106–7.PubMedCrossRef

38.

Hibberd PL, Tolkoff-Rubin NE, Doran M, et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. Online J Curr Clin Trials. 1992;Doc No 15:[4083 words; 46 paragraphs]

39.

Bottiger Y, Brattstrom C, Backman L, et al. Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. Br J Clin Pharmacol. 2005;60(5):566–9. doi:10.1111/j.1365-2125.2005.02475.x.PubMedCrossRef

40.

Moyses Neto M, Costa RS, Reis MA, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transplant. 1997;11(5 Pt 1):446–52.PubMed

41.

Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;(1):CD001321. doi:10.1002/14651858.CD001321.pub4

42.

Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131. doi:10.1002/14651858.CD005131.pub2

43.

Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59(4):645–51. doi:10.1016/j.eururo.2010.12.039.PubMedCrossRef

44.

Reid G, Bruce AW. Low vaginal pH and urinary-tract infection. Lancet. 1995;346(8991–8992):1704.PubMedCrossRef

45.

Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double-blind trial. Am J Transplant. 2005;5(1):125–30. doi:10.1111/j.1600-6143.2004.00649.x.PubMedCrossRef

46.

Antonopoulos IM, Piovesan AC, Falci Jr R, et al. Transurethral injection therapy with carbon-coated beads (durasphere) for treatment of recurrent pyelonephritis in kidney transplant patients with vesico-ureteral reflux to the allograft. Clin Transplant. 2010. doi:10.1111/j.1399-0012.2010.01242.x.

47.

Puri P, Ninan GK, Surana R. Subureteric Teflon Injection (STING). Results of a European survey. Eur Urol. 1995;27:71–5.PubMed

48.

Aaronson IA, Rames RA, Greene WB, et al. Endoscopic treatment of reflux: migration of teflon to the lungs and brain. Eur Urol. 1993;23:394–9.PubMed

49.

Ozok U, Eroglu M, Imamoglu A, et al. Subureteral dextranomer/hyaluronic acid copolymer injection for vesicoureteral reflux in transplant candidates. J Endourol. 2005;19:1185–7. doi:10.1089/end.2005.19.1185.PubMedCrossRef

50.

Hurst FP, Neff RT, Falta EM, et al. Incidence, predictors, and associated outcomes of prostatism after kidney transplantation. Clin J Am Soc Nephrol. 2009;4:329–36. doi:10.2215/CJN.04370808.PubMedCrossRef

51.

Sulikowski T, Tejchman K, Zietek Z, et al. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation. Transplant Proc. 2009;41:177–80. doi:10.1016/j.transproceed.2008.10.034.PubMedCrossRef

52.

Knispel HH, Klan R, Offermann G, Miller K. Transplantation in autosomal dominant polycystic kidney disease without nephrectomy. Urol Int. 1996;56:75–8.PubMedCrossRef

53.

Rozanski J, Kozlowska I, Myslak M, et al. Pretransplant nephrectomy in patients with autosomal dominant polycystic kidney disease. Transplant Proc. 2005;37:666–8. doi:10.1016/j.transproceed.2004.12.115.PubMedCrossRef

54.

Power RE, Hickey DP, Little DM. Urological evaluation prior to renal transplantation. Transplant Proc. 2004;36:2962–7. doi:10.1016/j.transproceed.2004.11.006.PubMedCrossRef

Title: Recurrent Urinary Tract Infections in Kidney Transplant Recipients
Authors: Subhashis Mitra
George John Alangaden
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 6/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-011-0210-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Urinary Tract Infections in Patients with Spinal Cord Injuries

Biopsy Procedures for Molecular Tissue Diagnosis of Invasive Fungal Infections

Treatment Duration of Febrile Urinary Tract Infections

Refractory Trichomoniasis in HIV-positive and HIV-negative Subjects

Assessing Responses to Treatment of Opportunistic Mycoses and Salvage Strategies

Gynecologic Clostridial Toxic Shock in Women of Reproductive Age

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage